{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:30:43Z","timestamp":1714523443882},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,30]]},"DOI":"10.7759\/cureus.59349","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T11:27:15Z","timestamp":1714476435000},"source":"Crossref","is-referenced-by-count":0,"title":["Vitiligo and Prostate Cancer Correlation"],"prefix":"10.7759","author":[{"given":"Richard L","family":"Siwicki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Shore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A","family":"Norman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29307","article-title":"Vitiligo: a narrative review","volume":"14","author":"Joge RR","year":"2022","unstructured":"Joge RR, Kathane PU, Joshi SH. Vitiligo: a narrative review. Cureus. 2022, 14:e29307. 10.7759\/cureus.29307","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14055","article-title":"Comorbidities in vitiligo: comprehensive review","volume":"57","author":"Dahir AM","year":"2018","unstructured":"Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. Int J Dermatol. 2018, 57:1157-64. 10.1111\/ijd.14055","journal-title":"Int J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15091847","article-title":"Cancer risks in vitiligo patients: a nationwide population-based study in Taiwan","volume":"15","author":"Li CY","year":"2018","unstructured":"Li CY, Dai YX, Chen YJ, et al.. Cancer risks in vitiligo patients: a nationwide population-based study in Taiwan. Int J Environ Res Public Health. 2018, 15:1847. 10.3390\/ijerph15091847","journal-title":"Int J Environ Res Public Health"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99786-9","article-title":"Reduced risk of skin cancer and internal malignancies in vitiligo patients: a retrospective population-based cohort study in Taiwan","volume":"11","author":"Weng YC","year":"2021","unstructured":"Weng YC, Ho HJ, Chang YL, Chang YT, Wu CY, Chen YJ. Reduced risk of skin cancer and internal malignancies in vitiligo patients: a retrospective population-based cohort study in Taiwan. Sci Rep. 2021, 11:20195. 10.1038\/s41598-021-99786-9","journal-title":"Sci Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163806","article-title":"The prevalence of vitiligo: a meta-analysis","volume":"11","author":"Zhang Y","year":"2016","unstructured":"Zhang Y, Cai Y, Shi M, et al.. The prevalence of vitiligo: a meta-analysis. PLoS One. 2016, 11:e0163806. 10.1371\/journal.pone.0163806","journal-title":"PLoS One"},{"key":"ref6","unstructured":"Gleason score. (2023). Accessed. March 27, 2024: https:\/\/my.clevelandclinic.org\/health\/diagnostics\/22087-gleason-score."},{"key":"ref7","unstructured":"Understanding the PI-RADS score and what it means for you. (2024). Accessed. March 27, 2024: https:\/\/sperlingprostatecenter.com\/understanding-the-pi-rads-score-and-what-it-means-for-you\/."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.11.024","article-title":"A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris","volume":"62","author":"Silverberg JI","year":"2010","unstructured":"Silverberg JI, Silverberg AI, Malka E, Silverberg NB. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol. 2010, 62:937-41. 10.1016\/j.jaad.2009.11.024","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0283","article-title":"Circulating vitamin D level and mortality in prostate cancer patients: a dose-response meta-analysis","volume":"7","author":"Song ZY","year":"2018","unstructured":"Song ZY, Yao Q, Zhuo Z, Ma Z, Chen G. Circulating vitamin D level and mortality in prostate cancer patients: a dose-response meta-analysis. Endocr Connect. 2018, 7:R294-303. 10.1530\/EC-18-0283","journal-title":"Endocr Connect"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.120720","article-title":"The role of vitamin D in melanogenesis with an emphasis on vitiligo","volume":"79","author":"AlGhamdi K","year":"2013","unstructured":"AlGhamdi K, Kumar A, Moussa N. The role of vitamin D in melanogenesis with an emphasis on vitiligo. Indian J Dermatol Venereol Leprol. 2013, 79:750-8. 10.4103\/0378-6323.120720","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20733","article-title":"Vitamin D deficiency in patients with vitiligo: a cross-sectional study from Basrah, Iraq","volume":"13","author":"Mahmmod Z","year":"2021","unstructured":"Mahmmod Z, Ismael DK. Vitamin D deficiency in patients with vitiligo: a cross-sectional study from Basrah, Iraq. Cureus. 2021, 13:e20733. 10.7759\/cureus.20733","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2009.7","article-title":"Vitamin D and prostate cancer risk: a review of the epidemiological literature","volume":"12","author":"Gupta D","year":"2009","unstructured":"Gupta D, Lammersfeld CA, Trukova K, Lis CG. Vitamin D and prostate cancer risk: a review of the epidemiological literature. Prostate Cancer Prostatic Dis. 2009, 12:215-26. 10.1038\/pcan.2009.7","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008923802001","article-title":"Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)","volume":"11","author":"Ahonen MH","year":"2000","unstructured":"Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control. 2000, 11:847-52. 10.1023\/a:1008923802001","journal-title":"Cancer Causes Control"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11375","article-title":"Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries","volume":"108","author":"Tuohimaa P","year":"2004","unstructured":"Tuohimaa P, Tenkanen L, Ahonen M, et al.. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer. 2004, 108:104-8. 10.1002\/ijc.11375","journal-title":"Int J Cancer"},{"key":"ref15","article-title":"Vitamin D for the management of prostate cancer","volume":"6","author":"Khan MA","year":"2004","unstructured":"Khan MA, Partin AW. Vitamin D for the management of prostate cancer. Rev Urol. 2004, 6:95-7.","journal-title":"Rev Urol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071639","article-title":"Current concepts of vitiligo immunopathogenesis","volume":"10","author":"Hla\u010da N","year":"2022","unstructured":"Hla\u010da N, \u017dagar T, Ka\u0161telan M, Brajac I, Prpi\u0107-Massari L. Current concepts of vitiligo immunopathogenesis. Biomedicines. 2022, 10:1639. 10.3390\/biomedicines10071639","journal-title":"Biomedicines"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1705536114","article-title":"Selective neutralization of IL-12 p40 monomer induces death in prostate cancer cells via IL-12-IFN-\u03b3","volume":"114","author":"Kundu M","year":"2017","unstructured":"Kundu M, Roy A, Pahan K. Selective neutralization of IL-12 p40 monomer induces death in prostate cancer cells via IL-12-IFN-\u03b3. Proc Natl Acad Sci U S A. 2017, 114:11482-7. 10.1073\/pnas.1705536114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-2207","article-title":"IFN\u03b3-induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via miRNA processing","volume":"79","author":"Lo UG","year":"2019","unstructured":"Lo UG, Pong RC, Yang D, et al.. IFN\u03b3-induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via miRNA processing. Cancer Res. 2019, 79:1098-112. 10.1158\/0008-5472.CAN-18-2207","journal-title":"Cancer Res"},{"key":"ref19","article-title":"Prostate specific antigen","author":"David MK","year":"2024","unstructured":"David MK, Leslie SW. Prostate specific antigen. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104499","article-title":"FDA approves ruxolitinib (Opzelura) for vitiligo therapy: a breakthrough in the field of dermatology","volume":"81","author":"Sheikh A","year":"2022","unstructured":"Sheikh A, Rafique W, Owais R, Malik F, Ali E. FDA approves ruxolitinib (Opzelura) for vitiligo therapy: a breakthrough in the field of dermatology. Ann Med Surg (Lond). 2022, 81:104499. 10.1016\/j.amsu.2022.104499","journal-title":"Ann Med Surg (Lond)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/246624-vitiligo-and-prostate-cancer-correlation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T11:27:27Z","timestamp":1714476447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/246624-vitiligo-and-prostate-cancer-correlation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.59349","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,30]]}}}